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Abstract
Context: Acromegaly (ACM) and Cushing’s disease (CD) are caused by functioning pituitary adenomas secreting growth hormone and ACTH respectively.
Objective: To determine the impact of race on presentation and postoperative outcomes
in adults with ACM and CD, which has not yet been evaluated.
Methods. This is a retrospective study of consecutive patients operated at a large-volume
pituitary center. We evaluated (1) racial distribution of patients residing in the metropolitan area (Metro, N = 124) vs 2010 US census data, and(2) presentation and postoperative
outcomes in Black vs White for patients from the entire catchment area (N = 241).
Results. For Metro area (32.4% Black population), Black patients represented 16.75% ACM
(P = .006) and 29.2% CD (P = .56). Among the total 112 patients with ACM, presentations with
headaches or incidentaloma were more common in Black patients (76.9% vs 31%White, P = .01).
Black patients had a higher prevalence of diabetes (54% vs 16% White, P = .005), significantly
lower insulin-like growth factor (IGF)-1 deviation from normal (P = .03) and borderline lower
median growth hormone levels (P = .09). Mean tumor diameter and proportion of tumors
with cavernous sinus invasion were similar. Three-month biochemical remission (46% Black,
55% White, P = .76) and long-term IGF-1 control by multimodality therapy (92.3% Black, 80.5%
White, P = .45) were similar. Among the total 129 patients with CD, Black patients had more
hypopituitarism (69% vs 45% White, P = .04) and macroadenomas (33% vs 15% White, P = .05).
At 3 months, remission rate was borderline higher in White (92% vs 78% Black, P = 0.08), which
was attributed to macroadenomas by logistic regression.
Conclusion. We identified disparities regarding racial distribution, and clinical and biochemical characteristics in ACM, suggesting late or missed diagnosis in Black patients.
Large nationwide studies are necessary to confirm our findings.
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Growth hormone (GH) and adrenocorticotropin (ACTH)secreting pituitary adenomas represent 10% to 20% of all
pituitary adenomas [1-5]. Hormone hypersecretion leads to
clinical manifestations of acromegaly (ACM) and Cushing’s
disease (CD). While the incidence rates are thought to be
low (approximately 0.3/100 000/year for each), ACM and
CD lead to comorbidities and decreased survival compared
with the general population. Timely treatment and biochemical control improve survival and comorbidities [6, 7].
Primary treatment for GH- and ACTH-secreting pituitary
adenomas is transsphenoidal surgery (TSS), and lower surgical morbidity and mortality were demonstrated at highcompared with low-volume centers [8-10].
According to the US Central Brain Tumor Registry, the
Black or African American population aged 15-39 have
a higher incidence of pituitary adenomas than the White
population (3.80 vs 3.15), with a further increase after age
40 (10.47 Black vs 4.99 White) [11]. Racial distribution
specifically in patients with GH- and ACTH-secreting pituitary tumors has not been studied. Also, no studies have
compared the clinical characteristics, biochemical parameters, imaging, and surgical biochemical remission between
the 2 racial groups.
Emory Pituitary Center is a high-volume tertiary referral facility in Atlanta, Georgia, a large city with a diverse population. The catchment area extends throughout
Georgia and surrounding states. Our study aims were to
(1) compare racial distribution of operated patients from
MetroATL with the US census, and (2) determine differences between clinical, biochemical, and radiological presentation and compare biochemical outcomes across racial
categories for patients from the entire catchment area of
the center.

in some race categories, we included “Other” as a racial
category in addition to White, Black, and Asian. We could
not ascertain the Hispanic vs non-Hispanic ethnicity due to
incomplete self-reporting.

Study Design
We performed a retrospective chart review to confirm
the preoperative biochemical diagnosis of ACM and CD
according to the most recent Endocrine Society guidelines [12, 13]. We retrieved information on demographic,
clinical, biochemical, and radiological characteristics, as
well as postoperative course through March 1, 2019. The
study was approved by the Emory University Hospital
Institutional Review Board (IRB00019648).
The study methodology had 2 parts corresponding to
each study aim. Part 1 pertained only to patients residing
in MetroATL, where we compared the racial distribution
with the 2010 US Census Bureau data. Using Google Maps
API (application programming interface), we plotted the
zip codes on the MetroATL counties map. We determined
the socioeconomic status (SES) based on the annual mean
household income (MHI) of each county’s data from the
2010 US Census Bureau data. Part 2 pertained to the entire patient population from the center’s entire catchment
area, where we analyzed race differences regarding clinical, biochemical, and radiological presentation, as well as
long-term postoperative outcomes.

Radiological Characteristics
We defined cavernous sinus invasion as tumor extension
beyond the line corresponding to the medial tangents of the
2 components of the intracavernous internal carotid artery.

Material and Methods
Patients

Clinical Outcomes

Of the 1836 TSSs for pituitary adenomas recorded in the
Emory Pituitary Center Database (REDcap 7.6.9) between
1994 and 2016, we identified all patients ages 18 or older
with ACM and CD. All patients were operated on by a dedicated pituitary neurosurgeon (N.M.O.). We determined
racial categories (Black or African American, American
Indian or Alaska Native, Asian, White or Caucasian, Native
Hawaiian or Other Pacific Islander, Other or Unknown or
Unavailable or Unreported) from the electronic medical
record containing self-reported data. For the purpose of
this study, due to the small number of minority patients

We defined postoperative ACM remission as normal
insulin-like growth factor (IGF)-1 and GH levels lower
than 1 ng/mL (fasting or after an oral glucose challenge) at
3 months postoperatively, and ACM recurrence as increased
IGF-1 levels during follow-up. When recurrence was suspected, additional confirmatory studies were performed,
including repeated IGF-1 and GH suppression tests. For
CD, remission was defined as normo- or hypocortisolism
at 3 months postoperatively, and recurrence as return of
hypercortisolism during follow-up. Normocortisolism was
confirmed by at least 2 normal Cushing screening tests
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postoperatively. Patients receiving medications to treat
GH or ACTH excess at 3 months postoperatively were
not considered in remission. At our center, surveillance of
Cushing’s disease patients no longer requiring hydrocortisone replacement consists of annual clinical evaluation and
screening with late night salivary cortisol. In patients who
are not good candidates for the late night salivary cortisol
test (eg, shift work, smoking), low-dose dexamethasone or
urinary free cortisol is used. Multiple screening tests are
used in patients with clinical suspicion of recurrence and
those with 1 abnormal screening test.
Adjuvant treatment with radiation and/or reoperation
were recorded.
Survival status was determined with PeopleSmart
(https://www.peoplesmart.com/) and confirmed with the
online obituary when applicable. Cause of death was not
available.

Statistical Methods
We used the 1-sample proportions test without continuity
correction to determine proportional representation of racial categories compared with the census data.
We reported normally distributed variables were as
mean and SD and non-normally distributed variables as
median and interquartile range (IQR).
We used the T-test to compare normally distributed
continuous variables among groups defined by gender
and change in remission rates, respectively. We used the
Kruskal–Wallis test and Wilcoxon score for non-normally
distributed continuous variables, and Fisher exact test for
categorical variables. We used logistic regression to determine influence of imaging (macroadenoma) and race on
postoperative remission in CD.
All statistical analyses were done using SAS v9.4 statistical software. P < .05 defined statistical significance.

Results
Racial distribution of the total catchment area patients
(112 ACM and 129 CD) is represented in Fig. 1.

Part 1: Geographical and Racial Patient
Distribution
These analyses pertain only to the MetroATL population
where a county-by-county comparison with the US census
was feasible. Racial composition of the MetroATL population according to the 2010 US census consisted of 55.5%
White, 32.4% Black, 4.8% Asian, and 7.3% other. The
total MetroATL population in 2010 was 5 286 728.
Acromegaly
Sixty patients with ACM resided in MetroATL. Patient racial categories were compared with MetroATL census data:
the proportions were lower for Black, higher for White, and
close to expected for Asian patients (Fig. 2). There was a
statistically significant difference regarding Black patients
vs Black census population (P = .006). When we evaluated
the racial distribution of patients from each county, with
counties arranged from least to most populated, White
patients followed the expected pattern of more patients
in more populous counties, while Black patients had consistently lower than expected representation. When we arranged the counties from lowest to highest socioeconomic
status, White patients were represented more broadly
across SES ranges.
Cushing’s disease
Sixty-five patients with CD lived in MetroATL. Patient racial distribution was grossly representative of the census
data with a slight underrepresentation of the Black population (Fig. 2) which was not statistically significant
(P = .56). Patients with CD were more evenly distributed

Figure 1. Racial distribution of all acromegaly (ACM, N = 112) and Cushing’s disease (CD, N = 129) operated patients.
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Figure 2. Racial distribution of Metropolitan Atlanta patients (60 ACM and 65 CD) and general population according to 2010 US census data.

within MetroATL counties than patients with ACM. When
we evaluated the racial distribution of patients from each
county, with counties arranged from least to most populated, the number of both Black and White patients was
higher in the more populous counties. When we ordered
the counties by mean household income, as the income increased, the number of White patients increased. We could
not identify trends in Black patient representation based on
the SES indicator above.
We analyzed patients’ racial distribution for DeKalb
County, where the tertiary referral pituitary center is located. DeKalb is 1 of the most populous counties within
MetroATL (691 893 inhabitants, according to the 2010
US census) with an average annual household income
that is close to the median income of the State of Georgia
($50 651). Compared with the 2010 US census (33.3%
White, 54.3% Black, 5.1% Asian, and 7.3% other), ACM
patient representation from this county showed racial disparities with fewer Black patients and more White and
Asian than expected (62.5% White, 37.5% Black, 12.5%
Asian, and 0% other). For patients with CD, the Black patient proportion was higher than expected (21.4% White,
71.4% Black, 0% Asian, and 7.1% other).

Part 2: All-patient Analyses From the Entire
Center Catchment Area
Presentation and comorbidities in the Black and White
racial groups
The analyses below pertain to all Black and White patients
operated on for ACM and CD from both within and outside MetroATL.
In ACM, gender representation and mean age were
similar for Black and White patients (Table 1). Peak age
at surgery was in the sixth life decade; however, only a
few Black patients were operated on after age 60 (Fig. 3).

The main reason for pituitary evaluation was different
across racial categories: fewer Black patients were tested
because of typical physical changes (23% Black vs 44%
White), while headaches/visual changes (46.1.% Black vs
17% White) and pituitary incidentalomas (30.8% Black vs
14% White) were more prevalent presentations in Black
patients. Gender analyses in Black patients indicated
presentation with typical physical changes in 3 women/0
men, headaches/visual changes 3 women/3 men, and pituitary incidentaloma in 2 women/2 men. Statistical differences were found when presentation with headaches
or incidentaloma were considered (76.9% Black vs 31%
White, P = .01). Black patients also had higher rates of diabetes mellitus and hypertension than White patients, with
the P value in the borderline statistical range for hypertension (Table 1). Mean body mass index (BMI) was similar
for Black and White patients. The proportion of patients
affected by malignancies was 15% in Black and 5.7% in
White patients (P = .22). Black patients had lower mean
IGF-1 deviations from normal and borderline lower GH
levels, while mean tumor diameter and proportion of tumors with cavernous sinus invasion were similar to White
patients (Table 1).
In CD, peak age at surgery for Black patients was
achieved in the fifth decade, followed by an abrupt decrease at older ages. White patients had a peak age in the
fourth decade, followed by a more gradual decrease (Fig.
3). Black patients had higher rates of preoperative hypopituitarism than White, but similar prevalence of DM and
hypertension (Table 2). The proportion of macroadenomas
was higher in Black patients (33% Black vs 15% White,
P = 0.05).
Postoperative outcomes across racial groups
Short-term (3 month) biochemical remission rates in ACM
were similar in Black (46%) and White (55%) patients
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Table 1. Preoperative characteristics of patients with acromegaly
Parameters
Demographic
Age at surgery (years)
Gender (% women)
BMI (kg/m2)
Comorbidities
Hypertension (%)
Diabetes mellitus (%)
Hypopituitarism (%)
Biochemistry
IGF-1 (nmol/L)
(IGF-1 – UNL)/UNL
GH (µg/L)
Imaging
Tumor diameter (cm)
Cavernous sinus invasion (%)

Black (13)

White (87)

P value

45.1 ± 13.1
54
32.4 ± 7.3

46.5 ± 13.0
53
30.1 ± 6.2

.75
1.00
.31

69
54
23

42
16
41

.08
.005
.24

86.7 ± 42.4
0.9 (0.4;1.0)
6.35 (4.8; 11.3)

107.7 ± 41.9
1.4 (0.9; 2.6)
11.2(4;38.5)

.06
.03
.09

2.1 ± 1.3
54

2.1 ± 1.5
39

.73
.37

Normally distributed variables are presented as mean ± SD and non-normally distributed as median (IQR).
Abbreviations: IGF-1, insulin-like growth hormone factor 1; GH, growth hormone; UNL, upper normal limit (age and gender appropriate).

Figure 3. Racial distribution of age at surgery in ACM (N = 112) and CD (N = 129) patients. The study included patients aged 18 and older.

(P = .76). Long-term disease outcome parameters in ACM are
presented in Table 3. There were 5 patient deaths (1 Black, 4
White) at a median of 5.9 years after surgery (IQR 3.3; 11.3).
Five patients (4.4%) had biochemical recurrence (4 White, 1
undeclared race) 2.7 years after surgery (IQR 1.6; 3.8).
Short-term (3 month) and long-term disease outcome
parameters in CD are presented in Table 4. Although remission rates at 3 months postoperatively were higher in
White (92%) than in Black patients (78%), this was borderline significant (P = .08). In addition, when the statistical
interaction between race, preoperative imaging, and remission was explored, the main determinant of remission was
presence of a macroadenoma. There were 4 patient deaths
(1 Black, 3 White) at a median of 3.3 years after surgery
(IQR 2.8; 4.2). Biochemical recurrence was encountered
in 1 Black and 15 White patients (P = .11) at a median of
2.2 years after surgery (IQR 1.0; 3.1).

Discussion
To our knowledge, this is the first study to evaluate impact of race on distribution, presentation, and outcomes
of patients operated on for ACM and CD. Our main findings were underrepresentation of Black patients and milder
biochemical phenotype in Black vs White patient groups
in ACM. In CD, there were no major disparities regarding
racial representation; however, there was a higher proportion of patients with macroadenoma and hypopituitarism and borderline lower remission rates at 3 months
postoperatively in Black than in White patients.

Part 1: Racial Frequency Disparities
Primary treatment for ACM and CD is TSS. Superior outcomes were demonstrated for patients undergoing TSS
at high-volume multidisciplinary centers by dedicated
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Table 2. Preoperative characteristics of patients with Cushing’s disease
Parameters
Demographic
Age at surgery (years)
Gender (% women)
Body mass index (kg/m2)
Comorbidities
Hypertension (%)
Diabetes mellitus (%)
Hypopituitarism (%)
Biochemistry
Serum cortisol (nmol/L)
Urinary free cortisol (nmol/day)
Plasma adrenocorticotropin (pmol/L)
Imaging
Tumor diameter (cm)
  Microadenoma (%)
  Macroadenoma(%)
   No adenoma (%)
Cavernous sinus invasion (%)

Black (27)

White (85)

P value

39.3 ± 9.5
74
36.0 ± 9.0

41.9 ± 12.3
86
35.9 ± 8.8

.39
.23
.98

78
41
69

69
41
45

.59
1.00
.04

700.7 ± 386.2
447.4 ± 470.3
18.3 ± 13.9

681.4 ± 366.9
592.6 ± 813.4
17.6 ± 10.5

.77
.44
.81

1.03 ± 0.6
56
33
11
15

0.81 ± 0.55
66
15
19
7

.10
.08
.05
.55
.25

Table 3. Postoperative course of patients with acromegaly
Black (13)
At 3 months
Biochemical remission (%)
Long term
Follow-up (years)
Biochemical recurrence (%)
Reoperation (%)
Radiation (%)
Last IGF-1 normal (%)
Mortality

White (87)

P value

Table 4. Postoperative course of patients with Cushing’s
disease (N = 129)
Black (27)

46

55

.76

4.4 ± 2.7
0
0
31
92.3
7.7

4.4 ± 3.6
4.7
8
30
80.5
4.6

.79
1.0
.59
1.00
.45
.51

neurosurgeons [9], including higher biochemical remission
rates for patients with ACM [14-17] and CD [18]. Several
studies indicated Black patients had the highest incidence
of all types of pituitary adenomas compared with White
and other racial categories [11, 19, 20]. Yet, some studies
pointed out Black patients were less likely to undergo TSS
for pituitary adenomas at high-volume centers [8, 10, 21,
22]. A National Inpatient Sample analysis indicated an increased number of White patients treated at centers with
>25 TSS/year in recent years; however, the opposite trend
was seen in minority patients [22]. The Emory Pituitary
Center is the only academic high-volume pituitary center in
the racially diverse region of Metro Atlanta, which offered
an opportunity to evaluate the proportional representation
of racial categories. Of note, our study was not designed
to calculate racial prevalence of ACM and CD in the region, as it only captured patients who received treatment
at our center.

At 3 months
Biochemical remission (%)
Long term
Follow-up (years)
Biochemical recurrence (%)
Reoperation (%)
Radiation (%)
Mortality

78
4.6 ± 3.4
3.85
7.4
18.5
3.7

White (85)

P value

92

.08

4.8 ± 4.2
18.1
20
16.5
3.5

.93
.11
.15
.77
1.0

We found that Black patients with ACM residing in
MetroATL were less likely to undergo TSS at our center
than White patients. To investigate this disparity, we
evaluated factors that are known to influence patient access, such as proximity to the center and SES. We found
that White patients resided in a wider geographical distribution than Black patients, and that Black patients were
underrepresented even in the most populous counties.
While we did not directly evaluate the patient SES and
health insurance, we used the US census zip code information to account for different counties racial representation
and mean household income. We noticed a wide White patient representation across SES ranges and could not identify any trends in Black patients.
For patients with CD, we did not find major disparities
regarding racial distribution. Previous studies from the
United States did not perform racial analyses; however, they
indicate more than 80% of patients with CD undergo TSS
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at large hospitals [21, 23, 24]. When we ordered the counties by mean household income, as the income increased,
the number of White patients increased. This is supported
by previous research showing that patients with higher
SES undergo more pituitary surgeries than lower SES patients [25], and that patients with private insurance who
live in wealthier neighborhoods have a higher likelihood
to undergo pituitary surgery at high-volume centers [21].
Further larger studies with more medical–social correlations are needed to understand racial representation disparities we found in patients with ACM but not in patients
with CD. The contrast between the higher incidence rates for
all types of pituitary adenomas in Black patients (from the
published studies) and our findings of underrepresentation
of Black patients in ACM raises several important questions. Do SES and distance to the pituitary center play a
role? While further insight can be provided by ascertaining
patients’ insurance status and individual income, we did
not identify major frequency disparities in CD. Even more,
the patient distribution in the county where the center is
located (with majority Black population) confirmed that
disparity occurred only in ACM. Are the features of acromegaly more difficult to recognize in Black patients?
Do GH-secreting adenomas have race-specific biological
characteristics?

Part 2: All-patient Analyses from the Entire Center
Geographical Catchment Area
Clinical, biochemical, and radiological presentation across
racial groups
We found that in patients with ACM, median IGF-1 deviation from normal was less pronounced in Black patients
than White, which may result in fewer of the striking physical changes of ACM. Anthropometric characteristics play a
role in recognition of the acromegaly phenotype. A survey
by the National Institute for Occupational Safety and
Health indicated the Black population typically had higher
mean scores for 13 of the 19 facial measures than the White
population, including wider faces as well as shorter, wider,
and shallower noses, and that race was second to gender to
impact the size and shape of the face [26]. Hence, recognition of typical facial features of ACM may be more difficult
in the Black population. In our study, 68% of Black patients
had imaging studies because of headaches or incidentally,
while typical phenotypical changes raised suspicion for
ACM in only 23%. This is an important educational point
as the number of patients with serendipitously detected
pituitary adenomas, including those secreting GH, has increased in recent years [27]. In the current study, Black patients with ACM had similar mean tumor size, proportion
of tumors with cavernous sinus invasion, and prevalence of
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hypopituitarism. The lower tumoral GH secretory output
may lead to less prominent physical changes, hence delays
in diagnosis and an increased number of comorbidities
in Black patients. Indeed, we found that more Black than
White patients had diabetes at the time of surgery, along
with a borderline higher prevalence of hypertension, despite similar mean BMI. Hypertension and diabetes are
also more common in Black than White patients in the
general population. However, the prevalence of these 2
comorbidities in our CD group was similar between Black
than White patients.
In patients with CD, we found that peak age at surgery
was 10 years later in Black than White patients, and that a
very small number of Black patients were diagnosed after
age 50. CD is suspected based on a cluster of manifestations such as centripetal weight gain, skin changes, uncontrolled diabetes, muscle weakness, or oligomenorrhea (in
women), and in some patients due to acute complications
such as thromboembolic disease, hypokalemia, and opportunistic infections. Our study raises the possibility of diagnostic delays in middle-aged Black women and potentially
missing CD diagnosis in older Black patients. The higher
likelihood of the Black general population to develop diabetes and hypertension than the White population [28, 29]
may contribute to the delay. Our study also found a higher
proportion of macroadenomas in Black than White patients (33% vs 15%); this would be interesting to explore
in larger studies given that the majority of ACTH-secreting
adenomas are small. There were no significant differences
regarding mean preoperative serum or 24-hour urinary
cortisol or plasma ACTH levels. Our literature search identified 1 study comparing Black with White patients which
included 129 children with CD (84 White and 9 Black).
In this study, both mean tumor diameter and mean urine
free cortisol levels were higher in the minority group [30].
Finally, our study found hypopituitarism, but not diabetes and hypertension, to be more common in Black than
White patients with CD. The etiology of hypopituitarism is
multifactorial, including hypercortisolism and tumor size.
Studies including a larger number of Black patients are required to elucidate this aspect.
Postoperative outcomes
Our study found similar postoperative remission rates in
Black and White patients with ACM, and a long-term biochemical control of more than 80% (as a result of surgery
alone or multimodality treatment with medications and/
or radiation) in both racial groups. In patients operated
on for CD, the short-term biochemical remission rate was
higher in White patients, although this did not reach statistical significance. Of note, there was a higher proportion
of pituitary macroadenomas in Black patients, which was
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a stronger predictor of remission than race in the logistic
regression. Presence of a macro- rather than microadenoma
on magnetic resonance imaging was associated with lower
remission rates than those with microadenomas in previous studies [31-33]. To date, only 1 study in children
with CD evaluated surgical remission rates across racial
groups and indicated a higher risk of persistent or recurrent hypercortisolism after 2.3 years (median follow-up) in
the Black and Hispanic group compared with non-Hispanic
White [30]. A Nationwide Inpatient Sample of 5527 adults
with CD indicated mortality and postoperative endocrine
and nonendocrine complications were not impacted by race;
however, biochemical remission rates were not reported, and
the proportion of minorities was small (6.5% Black) [24].
Study limitations are inherent to examination of rare diseases, including the retrospective design and small number
of non-White patients. Inter-racial comparisons were done
between the Black and White categories, due to the small
number of patients from other racial backgrounds. Still, this
is, to our knowledge, the first study evaluating the effect of
race in ACM and CD. We did not study the influence of ethnicities, as many patients did not fill this information in the
demographic questionnaires. State and regional registries
are necessary to elucidate the epidemiology, characteristics,
and treatment outcomes across minority populations. We
calculated the expected patient racial distributions using
the US census from 2010 while our study included patients
operated between 1994 and 2016. However, the proportion of the Black population in Metro Atlanta progressively
increased during the study span, and we did not identify
racial disparities in CD. These aspects strengthen the racial distribution disparity found in Black patients with
ACM. Finally, our SES analyses were exploratory in nature due to the small absolute number of Black patients.
We used the annual MHI of each county’s data from the US
census. Other factors such as healthcare insurance, access
to public transportation, and level of education remain to
be explored.
In conclusion, this is the first report that underlines
significant differences in clinical and biochemical presentation in Black vs White patients with ACM, which may
contribute to Black patients’ underrepresentation at our
large-volume center. Targeted educational and healthcare
delivery actions are needed to shorten the diagnostic delay
and increase minority population access to referral centers.
Future clinical studies are required to elucidate the race impact on ACM and CD, as well as disease-specific regional
and national registries.
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